866-997-4948(US-Canada Toll Free)

Polycystic Ovarian Syndrome - Pipeline Assessment and Market Forecasts to 2017

Published By :

GlobalData

Published Date : Sep 2010

Category :

Therapeutic Area

No. of Pages : 40 Pages


GlobalData, the industry analysis specialist, has released its new report, Polycystic Ovarian Syndrome Pipeline Assessment and Market Forecasts to 2017. The report is an essential source of information and analysis on the global Polycystic Ovarian Syndrome (PCOS) market. The report identifies the key trends shaping and driving the global PCOS market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global PCOS sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalDatas team of industry experts.

GlobalData estimated the Polycystic Ovarian Syndrome (PCOS) market to be worth $706m in 2009 and projects it to grow at a CAGR of 0.6% to reach $742m in 2017. The market is expected to decrease by 30.1% from $805m in 2011 to $563m in 2012. The decrease in the market will be due to the expiry of Letrozoles patent in the year 2011.The market will gain pace from 2013 and will grow to $742m in 2017. The slow growth rate is largely because of the under diagnosis of this syndrome. However, the market is driven by an increasing prevalence rate, diagnosis rate and treatment seeking rate. The rise in the prescription population will contribute to the growth of the PCOS market. Due to the presence of a large number of generic products and a weak pipeline, this market will not grow at a significant rate.

Scope

The report provides information on the key drivers and challenges of the Polycystic Ovarian Syndrome (PCOS) market. Its scope includes: 

  • Annualized global PCOS market revenues data from 2001 to 2009, forecast for eight years to 2017. 
  • Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends. Pipeline candidates fall under major therapeutic classes such as estrogen antagonists, female gamete inhibitor, insulin secretion inhibitor, HMG CoA inhibitor, Gastric and pancreatic lipase inhibitor and fats break down inhibitor.
  • Analysis of the current and future competition in the global PCOS market. Key market players covered are Merck KGaA, Catalysis SL and Amylin Pharma.
  • Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications. 
  • Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the PCOS therapeutics market

Reasons to buy

The report will enhance your decision making capability. It will allow you to:

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline. 
  • Develop business strategies by understanding the trends shaping and driving the global PCOS therapeutics market. 
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global PCOS therapeutics market in future. 
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors. 
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage. 
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships. 
  • Whats the next big thing in the global PCOS therapeutics market landscape? Identify, understand and capitalize.
Table Of Contents

1 Table of contents 3
1.1 List of Tables 5
1.2 List of Figures 5

2 Polycystic Ovarian Syndrome: Introduction 6
2.1 GlobalData Pipeline Report Guidance 6

3 Polycystic Ovarian Syndrome: Market Characterization 7
3.1 Market Overview 7
3.2 Polycystic Ovarian Syndrome Market Size 7
3.3 Polycystic Ovarian Syndrome Market Forecast and CAGR 8
3.4 Drivers and Barriers for the Polycystic Ovarian Syndrome Market 9
3.4.1 Drivers for Polycystic Ovarian Syndrome Market 9
3.4.2 Barriers for Polycystic Ovarian Syndrome Market 10
3.5 Opportunity and Unmet Need 11
3.6 Key Takeaway 12

4 Polycystic Ovarian Syndrome Market: Competitive Assessment 13
4.1 Overview 13
4.2 Strategic Competitor Assessment 13
4.3 Product Profile for the Major Marketed Products in the Polycystic Ovarian Syndrome Market 14
4.3.1 Clomid 14
4.4 Product Profile for Major Off-Label Drugs for Polycystic Ovarian Syndrome 16
4.4.1 Metformin 16
4.4.2 Letrozole 17
4.4.3 Flutamide 18
4.5 Key Takeaway 20

5 Polycystic Ovarian Syndrome: Pipeline Assessment 21
5.1 Overview 21
5.2 Strategic Pipeline Assessment 21
5.2.1 Technology Trends Analytic Framework 21
5.3 Molecule Profile for Major Pipeline Molecules under Clinical Development 22
5.3.1 Metformin + Exenatide 22
5.3.2 Follitropin alfa liquid formulation 23
5.3.3 Human Gonadotropin Hormone 23
5.3.4 Simvastatin 23
5.3.5 Orlistat 24
5.3.6 Clomiphene citrate + raloxifene 25
5.3.7 Oral DCI 25
5.3.8 Sibutramine + Loestrin (ethinyl estradiol) 25
5.3.9 Leuprolide acetate + Spironolactone 26
5.3.10 Oral Cinnamon Extract 26
5.3.11 Oral Contraceptives 26
5.3.12 Dietary Supplement: Diamel 27
5.3.13 Dietary Supplement: Flaxeed 27
5.3.14 Dietary Supplement: Alpha Lipoic Acid 27
5.3.15 Dietary Supplement: Vitamin D 28
5.4 Polycystic Ovarian Syndrome – Clinical Pipeline by Mechanism of Action 29
5.5 Polycystic Ovarian Syndrome – Pipeline by Phase of Clinical Development 30
5.5.1 Polycystic Ovarian Syndrome – Phase III Clinical Pipeline 30
5.5.2 Polycystic Ovarian Syndrome – Phase II Clinical Pipeline 31
5.5.3 Polycystic Ovarian Syndrome – Phase I Clinical Pipeline 31
5.6 Key Takeaway 31

6 Polycystic Ovarian Syndrome: Implications for the Future Market Competition 32

7 Polycystic Ovarian Syndrome: Future Players in Polycystic Ovarian Syndrome Market 33
7.1 Merck KGaA 33
7.1.1 Company Overview 33
7.1.2 Business Description 33
7.1.3 Female Sexual Dysfunction Portfolio 34
7.2 Catalysis SL 34
7.2.1 Company overview 34
7.2.2 Female Sexual Dysfunction Portfolio 34

8 Polycystic Ovarian Syndrome: Appendix 35
8.1 Definitions 35
8.2 Abbreviations 35
8.3 Scope of Pipeline Research 35
8.4 Research Methodology 36
8.4.1 Coverage 36
8.4.2 Secondary Research 36
8.4.3 Forecasting 36
8.4.4 Primary Research 39
8.4.5 Expert Panel Validation 39
8.5 Contact Us 39
8.6 Disclaimer 39
8.7 Sources 40

List of Table


Table 1: Polycystic Ovarian Syndrome Market, Global, Revenue ($m), 20012009 8
Table 2: Polycystic Ovarian Syndrome Market, Global, Forecast Revenue ($m), 20092017 9
Table 3: Major Marketed Products Analysis in the Polycystic Ovarian Syndrome Market, 2010 19
Table 4: Polycystic Ovarian Syndrome Phase III Clinical Pipeline, 2010 30
Table 5: Polycystic Ovarian Syndrome Phase II Clinical Pipeline, 2010 31
Table 6: Polycystic Ovarian Syndrome - Phase I Clinical Pipeline, 2010 31
Table 7: Merck KGaA Female Sexual Dysfunction Pipeline Products, 2010 34
Table 8: Catalysis SL Female Sexual Dysfunction Pipeline Products, 2010 34

List of Chart


Figure 1: Polycystic Ovarian Syndrome Market, Global, Revenues ($m), 20012009 8
Figure 2: Polycystic Ovarian Syndrome Market, Global, Forecast Revenues ($m), 20092017 9
Figure 3: Opportunity and Unmet Need in the Polycystic Ovarian Syndrome Market, 2010 11
Figure 4: Strategic Competitor Assessment of the Major Marketed Products for Polycystic Ovarian Syndrome, 2010 14
Figure 5: Technology Trends Analytics Framework of the Polycystic Ovarian Syndrome Pipeline, 2010 21
Figure 6: Technology Trends Analytic Framework of the Polycystic Ovarian Syndrome Pipeline Description, 2010 22
Figure 7: Polycystic Ovarian Syndrome Clinical Pipeline by Mechanism of Action, 2010 29
Figure 8: Polycystic Ovarian Syndrome Clinical Pipeline by Phase of Development, 2010 30
Figure 9: Polycystic Ovarian Syndrome Implications for Future Market Competition, 2010 32
Figure 10: GlobalData Market Forecasting Model 38

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *